- Shared genetic factors do not account for the observed co-occurrence of depression and
 autoimmune diseases in the UK Biobank.
- 3 Kylie P Glanville¹, Jonathan R I Coleman^{1,2}, Paul F O'Reilly³, *James Galloway⁴, *Cathryn M
- 4 Lewis^{1,2,5}
- 5 *Contributed equally and share senior authorship.
- 6 1. Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
- 7 Neuroscience, King's College London, London, GB
- 8 2. NIHR Biomedical Research Centre, South London and Maudsley NHS Trust, King's College
- 9 London, London, GB
- 10 3. Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, US
- 11 4. Department of Inflammation Biology, King's College London, London, GB
- 12 5. Department of Medical & Molecular Genetics, King's College London, London, GB
- 13

Address correspondence to Kylie P. Glanville, kylie.glanville@kcl.ac.uk; Social, Genetic and
 Developmental Psychiatry Centre; Institute of Psychiatry, Psychology & Neuroscience; King's
 College London, de Crespigny Park, London SE5 8AF; UK.

17 Abstract

Background: Epidemiological studies have shown increased comorbidity between depression and autoimmune diseases. The mechanisms driving the comorbidity are poorly understood, and a highly powered investigation is needed to understand the relative importance of shared genetic influences. We investigated the evidence for pleiotropy from shared genetic risk alleles between these traits in the UK Biobank (UKB).

23 **Methods:** We defined autoimmune and depression cases using information from hospital 24 episode statistics, self-reported conditions and medications, and mental health questionnaires. 25 Pairwise comparisons of depression prevalence between autoimmune cases and controls, and 26 vice-versa, were performed. Cross-trait polygenic risk score (PRS) analyses were performed to 27 test for pleiotropy, i.e. testing whether PRS for depression could predict autoimmune disease 28 status, and vice-versa.

Results: We identified 28k cases of autoimmune diseases (pooling across 14 traits), and 65k cases of depression. The prevalence of depression was significantly higher in autoimmune cases compared to controls, and vice-versa. PRS for myasthenia gravis and psoriasis were significantly associated with depression case-status ($p < 5.2x10^{-5}$, $R^2 <= 0.04\%$). PRS for depression were significantly associated with case-status for coeliac disease, inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and type 1 diabetes ($p < 5.8x10^{-5}$, R^2 range 0.06% to 0.27%).

- 36 Conclusions: Consistent with the literature, depression was more common in individuals with
- 37 autoimmune diseases compared to controls, and vice-versa, in the UKB. PRS showed some
- 38 evidence for involvement of shared genetic factors, but the modest R^2 values suggest that shared
- 39 genetic architecture accounts for only a small proportion of the increased risk across traits.

40 Introduction

41 There is substantial evidence that individuals with a history of autoimmune disease are at greater risk for developing depression¹⁻⁴, and that a history of depression increases risk for developing 42 autoimmune diseases^{5,6}. The mechanisms driving the bi-directional relationship are poorly 43 44 understood, but one contributory factor may be that these diseases share biological pathways. We and others have previously shown that there is no strong evidence for the involvement of 45 46 Human Leukocyte Antigen (HLA) alleles in risk for depression, suggesting that the Major 47 Histocompatibility Complex (MHC) does not harbor shared risk for depression and autoimmune diseases⁶⁻⁸. However, genetic risk for autoimmune diseases occurs across the genome⁹, and 48 49 pleiotropic effects outside the MHC may be involved in shared risk for depression and 50 autoimmune diseases.

51 Few studies have investigated evidence for genome-wide pleiotropy between depression and autoimmune diseases. Euesden, et al.¹⁰ found no evidence for association between polygenic risk 52 scores (PRS) for depression and risk for rheumatoid arthritis, or vice-versa. The Psychiatric 53 Genomics Consortium (PGC) indicated no evidence for significant genetic correlations (rG) 54 55 between depression and nine autoimmune diseases; the strongest correlation observed was between depression and inflammatory bowel disease (rG = .07, p = .06)¹¹. Recently, Liu, et al.⁶ 56 57 found no association between PRS for mental health disorders and risk for autoimmune diseases, and only a weak association between PRS for autoimmune diseases and risk for mental health 58 disorders. 59

medRxiv preprint doi: https://doi.org/10.1101/2020.12.08.20242495; this version posted December 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

60 In this study we extend previous work, leveraging the UK Biobank (UKB) to test for pleiotropy 61 between depression and autoimmune diseases with PRS methodology. Given the challenge of 62 reliably defining complex disease traits using large-scale data, we take two approaches to 63 defining autoimmune diseases and depression. We classified liberally-defined cases, based on a 64 single item endorsing diagnosis with an autoimmune disease, and then strictly-defined cases, based on multiple items. We take a similar approach to classifying depression by requiring a 65 66 greater number of endorsements in strictly-defined cases than liberally-defined cases. Liberally-67 defined cases increase the sample size, while strictly-defined cases will reduce the rate of misclassification. We perform cross-trait PRS analyses, testing for association between PRS for 68 autoimmune diseases and depression, and vice-versa. Motivated by the observation of sex-69 dependent genetic correlations between schizophrenia and autoimmune diseases¹², and by 70 71 higher prevalence in females of both depression and autoimmune diseases, we stratified PRS 72 analyses by sex. Our study is one of the largest to explore evidence for pleiotropy between depression and autoimmune diseases and elucidates the contribution of shared genetic 73 influences to the observed comorbidity. 74

75 Methods

76 Participants

77 The UKB is a prospective health study of 500,000 individuals in the United Kingdom. Participants 78 were identified through NHS patient registers if they were aged 40-69 during the recruitment 79 phase (2006-2010) and living in proximity to an assessment centre. Participants attended a baseline assessment and contributed health information via touchscreen questionnaires and 80 verbal interviews¹³. Subsets of participants completed repeat assessments: instance 1) n = 20,335 81 82 between 2012-2013; instance 2) n = 42,961 (interview) and n = 48,340 (touchscreen) in 2014; 83 and instance 3) n = 2,843 (interview) and n = 3,081 (touchscreen) in 2019. Participant data are 84 linked to Hospital Episode Statistics (HES) containing information on episodes of inpatient 85 hospital care. Episodes are coded at admission using the International Classification of Diseases, 10th Revision¹⁴ (ICD-10). Inpatients are assigned one primary code (reason for admission) and a 86 87 variable number of secondary codes. Additional data are available for psychiatric phenotyping, 88 including an online Mental Health Questionnaire (MHQ) completed by 157,366 participants in 2017¹⁵. The UKB received ethical approval from the North West - Haydock Research Ethics 89 Committee (reference 16/NW/0274). Participants provided electronic signed consent at 90 recruitment¹³. 91

92 Autoimmune phenotyping

Guided by studies that investigated the epidemiological relationship between autoimmune diseases and depression^{1,5} we identified cases for fourteen autoimmune diseases: pernicious anemia (PA), autoimmune thyroid disease (ATD), type 1 diabetes (T1D), multiple sclerosis (MS), myasthenia gravis (MG), coeliac, inflammatory bowel disease (IBD; includes crohn's disease and ulcerative colitis), psoriasis, ankylosing spondylitis (AS), polymyalgia rheumatica/giant cell arteritis (PR/GCA), psoriatic arthritis (PsA), rheumatoid arthritis (RA), sjögren syndrome (SS), and systemic lupus erythematosus (SLE).

Two sources of information were used to define autoimmune cases and controls. (1) HES: primary and secondary ICD-10 diagnoses recorded between April 1997 to October 2016 were identified from the UKB Data Portal Record Repository. (2) Verbal interview: we used participants' responses at baseline or instance 1 or 2 to determine self-endorsed medical conditions (past and current) and self-endorsed prescription medications (current). ICD-10 codes, self-endorsed conditions and medications used to define each autoimmune disease are listed in the Supplementary Material.

107 We took two approaches to defining autoimmune cases (Figure 1). To increase sample size, we 108 created 'possible' cases, comprising participants with an ICD-10 diagnosis or a self-endorsed 109 condition. To increase validity, we used multiple observations to create 'probable' cases. 110 Participants were coded as probable cases if at least two of ICD-10 diagnosis, self-endorsed 111 condition or medication were observed. More than one ICD-10 diagnosis for the corresponding

- autoimmune disease was also sufficient. A set of autoimmune controls was defined from
 participants with no ICD-10 diagnoses, self-endorsed conditions or medications for all fourteen
 autoimmune diseases. A single set of controls was used for all autoimmune diseases, given the
- 115 known comorbidity between them.



116

Figure 1: Autoimmune phenotyping approach. Cases are included in possible or probable if they fall within a
shaded area. Autoimmune medication was used as a confirmatory, but not a primary source of information,
because several medications are not disease-specific.

120

121 Depression phenotyping

We created two depression case groups: strictly-defined cases termed 'stringent depression' and liberally-defined cases termed 'any depression'. We have previously shown that SNP-based heritability increases with multiple endorsements of depression¹⁶. We therefore classified

'stringent depression' as participants endorsing at least three of the following depression measures: ICD-10 diagnoses (F32-F33.9); self-reported depression; self-reported antidepressant usage; single or recurrent depression (defined by Smith, et al.¹⁷ from responses to a touchscreen questionnaire completed at baseline by 172,751 participants); or answered 'yes' to the touchscreen questionnaire: "Have you ever seen a GP/psychiatrist for nerves, anxiety, tension or depression?".

We classified 'any depression' as participants who endorsed two or more depression measures, or if they met criteria for lifetime depression in the Composite International Diagnostic Interview (CIDI) assessed in the MHQ¹⁵. We classify cases defined from CIDI alone as 'any depression' not as 'stringent depression' because we previously observed lower SNP-based heritability in this group ($h_{SNP}^2 = 11\%$, SE = 0.008) compared to cases defined by three or more non-CIDI measures of depression ($h_{SNP}^2 = 19\%$, SE = 0.018)¹⁶.

Depression cases were screened for schizophrenia and bipolar according to any indication: ICD-10 diagnoses (F20-29, F30-31.9, F34-39); self-endorsed conditions (schizophrenia, mania, bipolar disorder or manic depression) or self-endorsed antipsychotic usage reported at baseline or instance 1 or 2; Bipolar Type I (Mania) or Bipolar Type II (Hypomania) according to the criteria adopted by Smith, et al.¹⁷; or indications of psychosis endorsed in the MHQ. A single set of depression controls was defined from participants who did not meet the criteria for depression, schizophrenia or bipolar.

Detail on the derivation of each indication of depression, schizophrenia and bipolar can be found
 in Supplementary Materials from our previous publication¹⁶.

146 Genetic quality control (QC)

The UKB performed preliminary QC on genotype data assayed for all participants¹³. Using genetic 147 148 principal components (PCs) provided by the UKB, we performed 4-means clustering on the first 149 two PCs to identify and retain individuals of European ancestry. QC was then performed using 150 PLINK v1.9¹⁸ to remove: variants with missingness > 0.02 (before individual QC), individuals with 151 missingness > 0.02, individuals whose self-reported sex was discordant from their genetic sex, 152 variants with missingness > 0.02 (after individual QC), variants departing from Hardy-Weinberg 153 Equilibrium (p < 10e-8), and variants with minor allele frequency (MAF) < 0.01. Relatedness kinship estimates provided by the UKB were used to identify pairs of related individuals (KING r² 154 > 0.044)¹⁹ and the GreedyRelated²⁰ algorithm used to remove one individual from each pair, 155 preferentially retaining individuals that survived QC. FlashPCA2²¹ was used to generate PCs for 156 the sub-set of individuals of European ancestry surviving QC. 157

158 Statistical analyses

We summarised sociodemographic data taken at baseline assessment: age, sex, socio-economic status (SES), body mass index (BMI) and current smoking status. We tested for significant differences in sociodemographic variables between cases and controls using Welch Two Sample t-tests in R v3.6²². We tested for significant differences in: 1) the prevalence of depression in

autoimmune cases compared to autoimmune controls, and 2) the prevalence of autoimmune diseases in depression cases compared to depression controls. These tests were performed for both probable/possible autoimmune cases and stringent/any depression, using 2-sample tests for equality of proportions in R v3.6²².

167 Summary statistics for autoimmune diseases and depression

168 We identified genome-wide association studies (GWAS) with publicly-available summary statistics for eight of the fourteen autoimmune diseases: coeliac²³, IBD²⁴, MS²⁵, MG²⁶, psoriasis²⁷, 169 PsA²⁸, RA²⁹, and SLE³⁰ (Supplementary Table 1). Summary statistics from GWAS using the 170 171 Immunochip were excluded as it does not provide genome-wide coverage. For Major Depressive Disorder (MDD), we used summary statistics from Wray, et al.¹¹, excluding UKB. QC was 172 173 performed on summary statistics to remove variants within the Major Histocompatibility 174 Complex (28.8 to 33.7 Mb), and variants in linkage disequilibrium ($r^2 > 0.1$) with the lead variant 175 within a 250kb region.

176 Polygenic risk score (PRS) analyses

PRS analyses were conducted using the PRSice-2 software³¹. To validate our phenotyping approach, we tested for association between PRS for eight autoimmune diseases and casecontrol status for the corresponding autoimmune diseases (possible and probable cases), and between PRS for MDD and case-control status for depression (any and stringent).

To investigate pleiotropy between autoimmune diseases and depression we performed crosstrait analyses, testing for association between 1) PRS for eight autoimmune diseases and casecontrol status for depression (any and stringent cases); and 2) PRS for MDD and case-control status for fourteen autoimmune diseases (possible and probable cases). To test for sex-specific effects, we performed cross-trait analyses in males and females separately.

186 For each test, PRS constructed at eight p-value thresholds (P_{T} ; 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 and 1.0) were regressed on case-control status using logistic regression, adjusting for the 187 188 following covariates: six PCs, genotyping batch, and assessment centre (n=128 variables). We 189 report p-values at the optimal $P_{\rm T}$ for each test of association. To control for multiple testing across 190 P_{T} (x8), and across tests of association (autoimmune PRS (x8) predicting any/stringent depression 191 (x2) in men and women (x2), n=32; and MDD PRS predicting possible/probable (x2) autoimmune 192 diseases (x14) in men and women (x2), n=56), a Bonferroni correction was applied to give a pvalue threshold for significance of 7.1×10^{-5} (0.05/704 tests, 704 = 8*(32+56)). Where sex-specific 193 194 associations were observed, sensitivity analyses were conducted to account for different sample 195 sizes between sexes. We tested for interactions between sex and PRS (at the optimal $P_{\rm T}$ from sex-196 specific tests) in the full sample (Phenotype ~ sex + PRS + sex*PRS + covariates). We report R^2 197 estimates transformed to the liability scale using the following population prevalences for 198 outcome traits: PA=0.1%³², ATD=2%³³, T1D=0.3%³⁴, MS=0.1%²⁵, MG=0.02%³⁵, coeliac=1%²³, 199 IBD=0.5%²⁴, psoriasis=2%³⁶, AS=0.55%³⁷, PR/GCA= 0.85%³⁸, PsA=0.5%²⁸, RA=1%³⁹, SS=0.7%⁴⁰, SLE=0.1%⁴¹ and MDD=15%¹¹. 200

201	AVENGEME ⁴² was used to estimate power to detect cross-trait PRS associations, assuming
202	varying degrees of genetic correlation (rG) between corresponding traits (rG 0.01 to 0.5). Power
203	was estimated for cross-trait analyses where summary statistics for both traits were publicly
204	available, such that SNP-based heritability (required for AVENGEME) could be estimated using
205	Linkage Disequilibrium Score Regression ⁴³ (Supplementary Figure 5). Power was estimated using
206	PRS at the optimal P_T identified in cross-trait association tests, and liberally-defined sample sizes.
207	Parameters used to estimate power are given in Supplementary Tables 6 and 7.

208 Results

209	A total of 28,479 individuals were identified as possible cases across fourteen autoimmune
210	diseases, and a sub-set of 16,824 (59.1%) met the stringent criteria for probable cases (refer
211	Supplementary Material for representation of the overlap between criteria used to define cases).
212	65,075 individuals met the criteria for any depression, 14,625 of whom met the criteria for
213	stringent depression. Sociodemographic characteristics for autoimmune and depression cases
214	and controls are summarised in Table 1. Overall, autoimmune and depression case groups
215	contained a higher proportion of females, had lower SES, higher smoking prevalence, and higher
216	BMI than their respective control groups, (N = $324,074$ autoimmune controls, N = $232,552$
217	depression controls, all p-values < 5x10 ⁻²¹ in pairwise comparisons).

Table 1: Sociodemographic information for autoimmune and depression cases and controls. Pop. Prev. = population prevalence estimate. UKB Prev. = prevalence of cases

in the UKB as a proportion of autoimmune/depression controls. TDI = Townsend Deprivation Index; negative scores indicate less deprivation. SD = standard deviation.

		Pop. Prev.	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)
Autoin	nmune Diseases (system/disease)					Possib	le						Probable			
Blood	Pernicious Anemia	0.10%	1,555	0.48%	58.9 (7.61)	71%	-0.85 (3.19)	13%	28.0 (5.55)	423	0.13%	60.1 (7.19)	72%	-0.99 (3.23)	12%	28.5 (5.34)
Endocrine system	Autoimmune Thyroid Disease	2.00%	859	0.26%	56.8 (7.75)	85%	-1.11 (3.05)	15%	27.4 (5.11)	607	0.19%	57.0 (7.64)	86%	-1.06 (3.03)	16%	27.8 (5.21)
	Type 1 diabetes	0.30%	2,751	0.84%	58.3 (7.80)	42%	-0.46 (3.39)	13%	30.1 (6.08)	2,292	0.70%	58.0 (7.85)	43%	-0.50 (3.39)	12%	29.9 (6.07)
/ous	Multiple Sclerosis	0.10%	1,683	0.52%	55.4 (7.52)	73%	-1.45 (3.01)	16%	26.9 (5.08)	1,154	0.35%	55.5 (7.45)	73%	-1.33 (3.06)	17%	26.9 (5.27)
Nen syst	Myasthenia Gravis	0.02%	234	0.07%	59.2 (7.39)	56%	-0.94 (3.27)	11%	29.0 (5.44)	147	0.05%	60.1 (7.09)	48%	-1.06 (3.32)	12%	29.3 (5.18)
tive	Coeliac	1.00%	2,364	0.72%	57.8 (7.79)	67%	-1.49 (2.99)	7%	25.8 (4.57)	1,260	0.39%	58.4 (7.66)	68%	-1.42 (3.03)	7%	25.8 (4.60)
Digest	Inflammatory Bowel Disease	0.50%	5,105	1.55%	57.4 (7.92)	51%	-1.27 (3.10)	10%	27.3 (4.70)	3,538	1.08%	57.3 (7.98)	50%	-1.28 (3.07)	9%	27.2 (4.63)
Skin	Psoriasis	2.00%	5,459	1.66%	56.8 (8.01)	46%	-1.05 (3.22)	15%	28.4 (5.17)	2,759	0.84%	57.1 (8.04)	42%	-0.90 (3.28)	16%	28.7 (5.26)
al system and ve tissue	Ankylosing Spondylitis	0.55%	1,344	0.41%	57.9 (7.47)	38%	-1.02 (3.21)	13%	27.8 (4.80)	413	0.13%	57.4 (7.57)	26%	-1.06 (3.22)	12%	27.9 (4.85)
	Polymyalgia Rheumatica/GCA	0.85%	1,627	0.50%	63.1 (5.16)	67%	-1.70 (2.79)	9%	28.3 (5.08)	898	0.28%	63.7 (4.58)	68%	-1.67 (2.75)	9%	28.4 (5.24)
	Psoriatic Arthritis	0.50%	1,107	0.34%	56.6 (7.48)	50%	-1.16 (3.18)	11%	29.0 (5.43)	779	0.24%	56.6 (7.52)	51%	-1.06 (3.23)	11%	29.3 (5.59)
skele [.] Inecti	Rheumatoid Arthritis	1.00%	6,360	1.92%	59.5 (7.06)	67%	-0.91 (3.29)	13%	28.5 (5.53)	3,451	1.05%	59.6 (7.01)	70%	-1.08 (3.18)	12%	28.2 (5.50)
isculo cor	Sjögren Syndrome	0.70%	647	0.20%	59.3 (7.10)	90%	-1.20 (3.03)	6%	27.1 (5.72)	389	0.12%	59.2 (7.26)	89%	-1.19 (3.10)	7%	27.0 (5.55)
Mu	Systemic Lupus Erythematosus	0.10%	624	0.19%	56.7 (8.18)	84%	-1.02 (3.21)	14%	27.3 (5.65)	362	0.11%	56.6 (8.00)	86%	-0.99 (3.15)	14%	27.3 (5.82)
	Any Autoimmune Disease	NA	28,479	8.08%	58.1 (7.73)	58%	-1.11 (3.17)	12%	27.9 (5.28)	16,824	4.94%	58.1 (7.73)	57%	-1.10 (3.17)	12%	28.0 (5.34)
	Autoimmune Controls	NA	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)
Depression					Any							Stringent				
	Depression	15%	65,075	21.86%	55.4 (7.86)	67%	-1.09 (3.14)	13%	27.8 (5.32)	14,625	5.92%	56.1 (7.88)	67%	-0.58 (3.35)	19%	28.9 (5.77)
	Depression Controls	NA	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)

The prevalence of any depression was significantly higher in autoimmune cases compared to autoimmune controls ($p = 6x10^{-177}$ for possible cases of any autoimmune disease versus controls, $p = 2x10^{-124}$ for probable cases of any autoimmune disease versus controls). The prevalence of stringent depression was significantly higher in autoimmune cases compared to autoimmune controls ($p = 3x10^{-124}$ 207 for possible cases of any autoimmune disease versus controls, $p = 6x10^{-163}$ for probable cases of any autoimmune disease versus controls, $p = 6x10^{-163}$ for probable cases of any autoimmune disease versus controls) (Table 2).

227	Table 2: Prevalence of depression within autoimmune cases compared to autoimmune controls, stratified by
228	possible/probable for autoimmune diseases, and any/stringent for depression cases. P-values from pairwise
229	comparisons of depression prevalence in autoimmune cases compared to autoimmune controls are shown in brackets.

		Depression prevalence in autoimmune traits								
		Any depression	on prevalence	Stringent depression prevalence						
A	utoimmune Trait	Possible Autoimmune	Probable Autoimmune	Possible Autoimmune	Probable Autoimmune					
	Autoimmune Controls	20	.6%	5.3	1%					
	Any Autoimmune Disease	28.9% (6x10 ⁻¹⁷⁷)	29.5% (2x10 ⁻¹²⁴)	10.8% (3x10 ⁻²⁰⁷)	11.5% (6x10 ⁻¹⁶³)					
Blood	Pernicious Anemia	35.8% (4x10 ⁻³⁶)	33.7% (4x10⁻ ⁸)	15.2% (1x10 ⁻³⁹)	16.6% (4x10 ⁻¹⁵)					
Fada aire autore	Autoimmune Thyroid Disease	35.1% (6x10 ⁻¹⁹)	34.7% (6x10 ⁻¹³)	13.7% (1x10 ⁻¹⁶)	13.4% (3x10 ⁻¹¹)					
Endocrine system	Type 1 diabetes	31.1% (3x10 ⁻³¹)	31.3% (1x10 ⁻²⁷)	14.1% (5x10 ⁻⁵⁹)	13.5% 5x10 ⁻⁴³)					
New your Custom	Multiple Sclerosis	39.3% (6x10 ⁻⁵⁶)	42.5% (3x10 ⁻⁵¹)	16.9% (5x10 ⁻⁵⁴)	20.0% (8x10 ⁻⁵⁷)					
Nervous System	Myasthenia Gravis	33.3% (5x10 ⁻⁵)	29.2% (3x10 ⁻²)	14.1% (5x10 ⁻⁶)	14.8% (4x10 ⁻⁵)					
	Coeliac	27.3% (3x10 ⁻¹²)	29.8% (2x10 ⁻¹²)	8.4% (4x10 ⁻⁸)	9.5% (7x10 ⁻⁸)					
Digestive system	Inflammatory Bowel Disease	24.9% (6x10 ⁻¹¹)	24.9% (3x10 ⁻⁸)	8.9% (8x10 ⁻²²)	9.1% (2x10 ⁻¹⁷)					
Skin	Psoriasis	26.8% (2x10 ⁻²²)	28.3% (1x10 ⁻¹⁷)	8.7% (4x10 ⁻²⁰)	9.9% (4x10 ⁻¹⁸)					
	Ankylosing Spondylitis	26.9% (5x10 ⁻⁷)	28.4% (5x10 ⁻⁴)	9.6% (7x10 ⁻⁹)	10.5% (9x10 ⁻⁵)					
	Polymyalgia Rheumatica/GCA	29.3% (2x10 ⁻¹³)	27.8% (5x10 ⁻⁶)	10.8% (3x10 ⁻¹⁵)	10.6% (1x10 ⁻⁸)					
Musculoskeletal system	Psoriatic Arthritis	31.8% (3x10 ⁻¹⁵)	34.3% (5x10 ⁻¹⁶)	10.2% (1x10 ⁻⁸)	13.0% (2x10 ⁻¹³)					
and connective tissue	Rheumatoid Arthritis	30.6% (5x10 ⁻⁶²)	29.4% (6x10 ⁻²⁸)	12.7% (3x10 ⁻⁹²)	12.1% (1x10 ⁻⁴⁵)					
	Sjögren Syndrome	40.7% (4x10 ⁻²⁵)	41.9% (1x10 ⁻¹⁷)	18.9% (2x10 ⁻²⁸)	18.9% (7x10 ⁻¹⁸)					
	Systemic Lupus Erythematosus	40.2% (2x10 ⁻²⁵)	44.5% (2x10 ⁻²²)	18.8% (6x10 ⁻³⁰)	22.2% (8x10 ⁻²⁷)					

230	The prevalence of possible cases of any autoimmune disease was significantly higher in depression cases
231	compared to depression controls (p = $6x10^{-177}$ for any depression versus controls, p = $3x10^{-207}$ for
232	stringent depression versus controls). The prevalence of probable cases of any autoimmune disease was
233	significantly higher in depression cases compared to depression controls ($p = 2x10^{-124}$ for any depression
234	versus controls, $p = 6x10^{-163}$ for stringent depression versus controls) (Table 3).

Table 3: Prevalence of autoimmune diseases within depression cases compared to depression controls, stratified by possible/probable for autoimmune diseases, and stringent/any for depression cases. P-values from pairwise comparisons of autoimmune prevalence in depression cases compared to depression controls are shown in brackets.

		Autoimmune prevalence in depression								
		Possible au	toimmune prevale	ence	Probable autoimmune prevalence					
Αι	utoimmune Trait	Any Depression	Stringent Depression	Depression Controls	Any Depression	Stringent Depression	Depression Controls			
	Any Autoimmune Disease	10.48% (6x10 ⁻¹⁷⁷)	14.27% (3x10 ⁻²⁰⁷)	6.94%	6.59% (2x10 ⁻¹²⁴)	9.48% (6x10 ⁻¹⁶³)	4.19%			
Blood	Pernicious Anemia	0.77% (4x10 ⁻³⁶)	1.17% (1x10 ⁻³⁹)	0.36%	0.19% (4x10 ⁻⁸)	0.35% (4x10 ⁻¹⁵)	0.10%			
Endoaring system	Autoimmune Thyroid Disease	0.41% (6x10 ⁻¹⁹)	0.58% (1x10 ⁻¹⁶)	0.20%	0.28% (6x10 ⁻¹³)	0.39% (3x10 ⁻¹¹)	0.14%			
Endocrine system	Type 1 diabetes	1.20% (3x10 ⁻³¹)	2.07% (5x10 ⁻⁵⁹)	0.69%	1.02% (1x10 ⁻²⁷)	1.65% (5x10 ⁻⁴³)	0.58%			
Names Contant	Multiple Sclerosis	0.87% (6x10 ⁻⁵⁶)	1.31% (5x10 ⁻⁵⁴)	0.35%	0.63% (3x10 ⁻⁵¹)	1.02% (8x10 ⁻⁵⁷)	0.22%			
Nervous System	Myasthenia Gravis	0.11% (5x10 ⁻⁵)	0.17% (5x10 ⁻⁶)	0.05%	0.06% (3x10 ⁻²)	0.12% (4x10 ⁻⁵)	0.04%			
Dissetting system	Coeliac	0.92% (3x10 ⁻¹²)	1.08% (4x10 ⁻⁸)	0.64%	0.54% (2x10 ⁻¹²)	0.64% (7x10 ⁻⁸)	0.33%			
Digestive system	Inflammatory Bowel Disease	1.82% (6x10 ⁻¹¹)	2.56% (8x10 ⁻²²)	1.43%	1.28% (3x10 ⁻⁸)	1.85% (2x10 ⁻¹⁷)	1.00%			
Skin	Psoriasis	2.05% (2x10 ⁻²²)	2.55% (4x10 ⁻²⁰)	1.46%	1.10% (1x10 ⁻¹⁷)	1.47% (4x10 ⁻¹⁸)	0.73%			
	Ankylosing Spondylitis	0.52% (5x10 ⁻⁷)	0.72% (7x10 ⁻⁹)	0.37%	0.17% (5x10 ⁻⁴)	0.25% (9x10 ⁻⁵)	0.11%			
	Polymyalgia Rheumatica/GCA	0.66% (2x10 ⁻¹³)	0.93% (3x10 ⁻¹⁵)	0.42%	0.35% (5x10 ⁻⁶)	0.51% (1x10 ⁻⁸)	0.23%			
Musculoskeletal	Psoriatic Arthritis	0.50% (3x10 ⁻¹⁵)	0.58% (1x10 ⁻⁸)	0.28%	0.38% (5x10 ⁻¹⁶)	0.51% (2x10 ⁻¹³)	0.19%			
connective tissue	Rheumatoid Arthritis	2.66% (5x10 ⁻⁶²)	4.14% (3x10 ⁻⁹²)	1.59%	1.42% (6x10 ⁻²⁸)	2.23% (1x10 ⁻⁴⁵)	0.89%			
	Sjögren Syndrome	0.34% (4x10 ⁻²⁵)	0.55% (2x10 ⁻²⁸)	0.13%	0.21% (1x10 ⁻¹⁷)	0.33% (7x10 ⁻¹⁸)	0.08%			
	Systemic Lupus Erythematosus	0.36% (2x10 ⁻²⁵)	0.59% (6x10 ⁻³⁰)	0.14%	0.23% (2x10 ⁻²²)	0.39% (8x10 ⁻²⁷)	0.08%			

Testing for same-trait PRS associations, PRS for MDD were significantly associated with any depression case-status ($p < 5x10^{-324}$, $R^2 = 1.48\%$,) and stringent depression case-status ($p = 2x10^{-228}$, $R^2 = 2.23\%$). PRS for autoimmune diseases were significantly associated with both possible and probable case-control status for the corresponding diseases (Figure 2). The variance in liability, R^2 , explained by PRS was higher in strictly-defined compared to liberally-defined phenotypes. Most results were highly significant (p < $6x10^{-29}$), except myasthenia gravis ($p < 7x10^{-3}$), which has the smallest sample size of less than 250 cases, and psoriatic arthritis ($p < 3 \times 10^{-6}$) where the discovery GWAS has only 1430 cases.



Figure 2: Variances in autoimmune liability explained by PRS for the corresponding autoimmune diseases. The number of cases are shown at the top of the plot (possible = blue, probable = red). P-values are shown atop each bar.

249

In the prediction of depression from autoimmune PRS (Figure 3), the PRS for myasthenia gravis were significantly associated with case-status for any depression ($p = 5.2 \times 10^{-5}$, $R^2 = 0.01\%$) and stringent depression ($p = 1.6 \times 10^{-5}$, $R^2 = 0.04\%$). PRS for psoriasis were significantly associated with case-status for

any depression (p = 8.7×10^{-6} , $R^2 = 0.01\%$). No other autoimmune disease PRS predicted depression casecontrol status, and no sex-specific analyses met the Bonferroni-corrected threshold for significance. The R^2 values for variance explained in depression by autoimmune PRS are all very low, at <0.1%, and substantially lower than the R^2 for autoimmune diseases (Figure 2).





Figure 3: Variances in depression liability explained by PRS for autoimmune diseases (x-axis). Asterisks denote associations with p-values < 7.1x10⁻⁵, meeting Bonferroni correction. Number of cases for depression phenotypes: Any (combined) = 65,075; Any (female) = 43,413; Any (male) = 21,662; Stringent (combined) = 14,625; Stringent (female) = 9,738; Stringent (male) = 4,887.

263

Genetic liability for MDD was significantly associated with six autoimmune diseases: coeliac, inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and type 1 diabetes (all p-values < 5.8x10⁻⁵, *R*² range between 0.06% and 0.27%) (Figure 4). For three, the association with MDD was observed in probable and possible cases (psoriasis, rheumatoid arthritis and type 1 diabetes). For coeliac and inflammatory bowel disease, the association was only in possible cases. For psoriatic arthritis,

269	the association was only in probable cases. For all significant associations observed, higher PRS increased
270	risk for the outcome phenotype, except for coeliac, where higher MDD PRS was associated with reduced
271	risk (p = 6x10 ⁻⁸ , R ² = 0.17%, beta = -0.11, SE = 0.02, in the combined sample).

272 Sex-specific associations were observed, primarily in female autoimmune cases (coeliac, inflammatory bowel disease, type 1 diabetes and rheumatoid arthritis, all $p < 4.5 \times 10^{-5}$). Association in males was 273 observed in psoriasis (possible cases, $p = 5.8 \times 10^{-5}$), and in rheumatoid arthritis (possible cases, $p = 1.6 \times 10^{-5}$) 274 275 ⁵). The most consistent results were observed in rheumatoid arthritis, where the sample size was largest, 276 with five of the six analyses reaching Bonferroni threshold for significance (all $p < 4.5 \times 10^{-5}$, R^2 range 277 between 0.07% and 0.1%). However, there was no evidence for a significant interaction between sex 278 and PRS in the combined samples of men and women (all p > 0.02), indicating that sex-specific 279 associations were generally influenced by sample size.

Full results of each test are shown in Supplementary Tables 2 to 5 and Supplementary Figures 1 to 4.



282

Figure 4: Variances in autoimmune liability (x-axes) explained by PRS for MDD. Asterisks denote associations with pvalues < 7.1x10⁻⁵, meeting Bonferroni correction. Number of cases for the autoimmune diseases are given in Table 1.

Power analyses showed that, in the prediction of any depression from autoimmune PRS, there was 80% power to detect associations assuming modest levels of underlying genetic correlation (rG) below 0.15.
There were two exceptions; multiple sclerosis and myasthenia gravis, where the underlying rG would need to approach ~0.3 to achieve 80% power (Supplementary Figure 6). In the prediction of possible

- 290 autoimmune diseases from depression PRS, there was 80% power to detect associations assuming rG
- 291 <0.1, again with the exception myasthenia gravis, where an rG ~0.18 would be required to achieve 80%
- 292 power (Supplementary Figure 7).

293 Discussion

294 Motivated by epidemiological findings of a bi-directional relationship between depression and 295 autoimmune diseases, we tested for evidence of pleiotropy between traits, adopting both liberal and 296 strict phenotyping approaches to define cases in the UKB. We showed modest association of PRS from 297 autoimmune diseases with MDD, and slightly stronger associations of MDD PRS with autoimmune 298 diseases. These observations suggest only a minor component of observed comorbidity is due to shared 299 genetics between depression and autoimmune diseases.

We made three key observations: 1) Phenotypic variance explained by PRS for corresponding traits was higher in strictly-defined than liberally-defined cases, indicating more rigorous phenotyping improved the validity of autoimmune and depression cases; 2) The phenotypic overlap between depression and autoimmune diseases was consistent with the literature – depression was more common in individuals with autoimmune diseases, and vice-versa; 3) Cross-trait PRS analyses identified significant associations between depression and some autoimmune diseases, but with effect sizes indicating the existence of a shared biological component of modest effect on the observed comorbidity.

Our phenotyping approach for autoimmune diseases used both strictly-defined and liberally-defined cases, integrating the multiple sources of UKB data. PRS constructed for eight autoimmune diseases predicted case-control status, increasing confidence in the robustness of case definition. The phenotypic variance explained was higher in strictly-defined cases, potentially reflecting greater specificity; identifying individuals with multiple endorsements for a disease (e.g. hospital admission and prescription

medication) reduces the probability of misclassifying controls as cases. Conversely, the criteria for
liberally-defined cases increases sample size, but may induce misclassification of controls as cases.

For each of the fourteen autoimmune diseases considered, cases had higher frequencies of depression than controls, recapitulating the effect observed in epidemiological studies. Similarly, the prevalence of each autoimmune disease was significantly higher in depression cases compared to controls. Prevalence estimates reported here are cross-sectional, and we lack information on the temporal relationship between traits.

The findings from cross-trait PRS analyses identified significant associations, although observed effect 319 sizes were small, ranging between $R^2 = 0.01\%$ and 0.27%. For three traits, we observed significant 320 321 associations in liberally-defined, but not strictly-defined cases (psoriasis PRS was associated with any 322 depression, MDD PRS was associated with possible coeliac and inflammatory bowel disease). In contrast, 323 MDD PRS was associated with probable, but not possible, psoriatic arthritis, suggesting misclassification 324 in possible cases. Misclassification bias may vary across diseases; some autoimmune diseases may be 325 more prone to misclassification with other autoimmune diseases, whilst other diagnoses may misclassify 326 with non-inflammatory conditions. For example, osteoarthritis (non-inflammatory) may misclassify as 327 psoriatic arthritis in the absence of multiple-item endorsement to increase diagnosis validity.

Cross-trait PRS analyses identified some sex-dependent associations. MDD PRS were associated with psoriasis in males, and MDD PRS were associated with coeliac, inflammatory bowel disease and type 1 diabetes in females. However, sensitivity analyses revealed no evidence for significant interactions between PRS and sex in the combined sample, indicating that sex-dependent associations were generally

332 driven by different sample sizes in sex-stratified analyses. Rheumatoid arthritis was the most common 333 autoimmune disease and showed the most consistency in cross-trait associations; MDD PRS were significantly associated with rheumatoid arthritis in all case groups, except probable males. This is in 334 contrast with Euesden, et al.¹⁰, who found no evidence for association between PRS for depression and 335 risk for rheumatoid arthritis, but in a substantially smaller sample of 226 cases. Liu, et al.⁶ also found no 336 337 evidence for association between a composite mental health disorder PRS and risk for autoimmune 338 diseases, but also in a smaller sample of 1,383 individuals with any of seven autoimmune diseases. 339 However, a composite PRS for autoimmune diseases did show weak association with case-control status in a sample of 43,902 individuals with any of six mental health disorders in the Liu, et al.⁶ study. This 340 highlights the importance of sample size, and our study benefits from the scale of the UKB, where power 341 342 calculations indicated our investigation was able to detect even modest pleiotropic effects. However, 343 there were exceptions for rare autoimmune diseases, where larger samples would be required to reject 344 the presence of a weak genetic correlation with depression.

345 The weak genetic contribution suggests that another mechanism may be driving or contributing to the bi-directional relationship between autoimmune diseases and depression⁴⁴. Inflammatory factors 346 347 underlying some cases of depression could provide a common biological pathogenesis with autoimmune diseases. Lynall, et al.⁴⁵ observed increased immune cell counts in depression cases compared to 348 349 controls, and identified a sub-group of cases with elevated inflammatory markers who presented with 350 more severe depression than uninflamed cases. In our data, we considered whether R^2 values mirrored 351 the inflammatory burden of autoimmune diseases, recognizing that some diagnoses have much higher 352 levels of systemic inflammation (e.g. IBD or RA) than others (e.g. Coeliac). Although subtle differences

were present, in absolute terms variation was small and it was not possible to infer a 'dose-response'
 effect between autoimmune disease PRS and depression.

355 Environmental risk factors such as BMI and childhood maltreatment increase risk of both depression and autoimmune diseases and would contribute to the bi-directional effect^{46,47}. Similarly, some treatments 356 357 for depression (antidepressants) and autoimmune diseases (steroids) are obesogenic and may increase 358 comorbidity. Diagnosis with autoimmune disease increases risk of depression due to psychological factors in adjusting to a chronic disorder and changes in behaviour such as reduced exercise. Health 359 360 related behaviours that are elevated in depression (smoking, poor diet and reduced physical activity) 361 increase risk for autoimmune diseases. These mechanisms may not be independent of joint genetic 362 contributors. For example, shared inflammatory mechanisms would lead to horizontal pleiotropy, where genetic variants directly affect both disorders, and vertical pleiotropy can arise through environmental 363 364 risk factors where genetic variation influences one trait through mediation on another trait.

365 Limitations

A healthy volunteer bias has been observed in the UKB⁴⁸, and is a noted limitation of the study. However, it has been proposed that this bias may attenuate, but not invalidate, exposure-outcome relationships⁴⁹. A further limitation of the ability to extrapolate our results is the lack of representation in individuals of diverse ancestries. The literature has demonstrated attenuation in PRS analyses where training and target samples are drawn from different ancestral populations⁵⁰, highlighting the need to perform GWAS in diverse ancestries. This limitation may have broader implications than would otherwise be the case

for some conditions, such as SLE, which disproportionately affect individuals of African and Asianancestry.

Although every effort has been made to address the potential for misclassification bias through the criteria for multiple-item endorsements in strictly-defined cases, the approach remains imperfect. The impact of misclassification depends on the effect directionality, and it is possible that mis-estimation of associations has occurred. However, it is our contention that even misclassification of moderate size would have only marginal impacts on the inferences made above.

379 Conclusions

380 We identified cases and controls for depression and fourteen autoimmune diseases in the UKB, using 381 both strict and liberal phenotyping. PRS analyses indicated that strict phenotyping improved the validity of cases, demonstrating that multiple UKB variables can be leveraged to increase specificity. Consistent 382 383 with the literature, we found that depression was enriched in autoimmune cases, and vice-versa. Despite 384 having power to detect subtle pleiotropic effects, we found little evidence that shared genetic factors 385 have a meaningful influence on the observed co-occurrence of depression and autoimmune diseases in 386 the UK Biobank. The limited shared genetic component will make only a modest contribution to the bidirectional disease risks, and shared environmental factors, including health-related characteristics and 387 388 stressful life events, may be important. Future studies leveraging phenotypic, genetic, diagnostic, 389 treatment and environmental risk factors may be necessary to unpick the mechanisms contributing to 390 shared risks for autoimmune diseases and depression. In particular, future research should consider the

391 psychological impacts of autoimmune disease while remaining cognizant of the need to consider and

392 treat the two diseases in parallel.

393 Funding

This work was supported by the UK Medical Research Council (PhD studentship to KPG; grant MR/N015746/1). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

399 Acknowledgements

400 We thank participants and scientists involved in making the UK Biobank resource available 401 (http://www.ukbiobank.ac.uk/). The UKB received ethical approval from the North West - Haydock Research Ethics Committee (reference 16/NW/0274). This study was conducted under application 402 403 number 18177. We thank the research participants and employees of 23andMe for making this work 404 possible. The MDD GWAS summary statistics results from 23andMe were available through a Data 405 Transfer Agreement between 23andMe, Inc., and King's College, London. Only summary statistics were 406 shared with no individual level data. 23andMe participants provided informed consent and participated 407 in the research online. The 23andMe protocol was approved by an external Association for the 408 Accreditation of Human Research Protection Programs accredited Institutional Review Board, Ethical 409 and Independent Review Services. Participants were included in the analysis on the basis of consent 410 status as checked at the time data analyses were initiated. Statistical analyses were carried out on the 411 King's Health Partners High Performance Compute Cluster funded with capital equipment grants from 412 the GSTT Charity (TR130505) and Maudsley Charity (980). We thank Nick Dand, Satveer Mahil and

- 413 Catherine Smith of King's College London for their contribution in identifying medications used in the
- 414 treatment of Psoriasis in the UKB.

415 Data Availability

- 416 Available from UK Biobank subject to standard procedures (www.ukbiobank.ac.uk). The full GWAS
- 417 summary statistics for the 23andMe discovery data set will be made available through 23andMe to
- 418 qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe
- 419 participants. Please visit <u>https://research.23andme.com/collaborate/#publication</u> for more information
- 420 and to apply to access the data.

421 Author contributions

422 Conceptualisation and study design: KPG, CML, JG, PFO. Analysis and manuscript: KPG. Analytical 423 consultation and interpretation: CML, JG, PFO, JRIC. UKB data curation and management: JRIC, KPG. 424 Genetic data preparation: JRIC, KPG. Project supervisors: CML, JG, PFO. All authors critically edited the 425 paper.

426 Declaration of Interest

427 CML is a member of the SAB for Myriad Neuroscience. The remaining authors declare no competing 428 interests.

429 References

- Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al.
 Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders A
 Nationwide Study. JAMA Psychiatry. American Medical Association; 2013
 Aug;70(8):812–20.
- Anderson RJ, Freedberg KA, Clouse RE, Lustman PJ. The Prevalence of Comorbid
 Depression in Adults With Diabetes. Diabetes Care. 2001 Jun;24(6):1069–78.
- 436 3. Patten SB, Beck CA, Williams JVA, Barbui C, Metz LM. Major depression in multiple
 437 sclerosis: A population-based perspective. Neurology. 61st ed. 2003 Dec;:1524–7.
- 4. Kurina L, Goldacre M, Yeates D, Gill L. Depression and anxiety in people with
 inflammatory bowel disease. Journal of Epidemiology and Community Health. BMJ
 Publishing Group; 2001 Oct 1;55(10):716–20.
- Andersson NW, Gustafsson LN, Okkels N, Taha F, Cole SW, Munk-Jorgensen P, et al.
 Depression and the risk of autoimmune disease: a nationally representative, prospective
 longitudinal study. Psychol Med. Cambridge University Press; 2015 Dec;45(16):3559–
 69.
- Liu X, Nudel R, Thompson WK, Appadurai V, Schork AJ, Buil A, et al. Genetic factors underlying the bidirectional relationship between autoimmune and mental disorders – findings from a Danish population-based study. Brain, Behavior, and Immunity.
 Academic Press; 2020 Jun 11.
- Glanville KP, Coleman JRI, Hanscombe KB, Euesden J, Choi SW, Purves KL, et al.
 Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly
 Associated With Depression. Biological Psychiatry. Elsevier; 2020 Mar 1;87(5):419–30.
- Nudel R, Benros ME, Krebs MD, Allesøe RL, Lemvigh CK, Bybjerg-Grauholm J, et al.
 Immunity and mental illness: findings from a Danish population-based immunogenetic study of seven psychiatric and neurodevelopmental disorders. European Journal of Human Genetics. Nature Publishing Group; 2019 Apr 11;8(1):1.
- 456 9. Hu X, Daly M. What have we learned from six years of GWAS in autoimmune diseases,
 457 and what is next? Current Opinion in Immunology. Elsevier Current Trends; 2012 Oct
 458 1;24(5):571–5.
- 459 10. Euesden J, Danese A, Lewis CM, Maughan B. A bidirectional relationship between
 460 depression and the autoimmune disorders New perspectives from the National Child
 461 Development Study. PLOS ONE. Public Library of Science; 2017 Mar;12(3):1–14.

- Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al.
 Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics. Nature Publishing Group; 2018
 May;50:668–81.
- Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Han
 B, Wu Y, Mignot E, Ollila HM, et al. Cross-disorder analysis of schizophrenia and 19
 immune-mediated diseases identifies shared genetic risk. Human Molecular Genetics.
 2019 Jun 18.
- 470 13. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
 471 resource with deep phenotyping and genomic data. Nature. Nature Publishing Group;
 472 2018 Oct 1;562(7726):203–9.
- 473 14. World Health Organization. International Classification of Diseases (10th Edition).
 474 Geneva: World Health Organisation; 1992.
- 15. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in
 UK Biobank development, implementation and results from an online questionnaire
 completed by 157 366 participants: a reanalysis. BJPsych Open. Cambridge University
 Press; 2020 Mar 1;6(2):e18.
- Glanville KP, Coleman JR, Howard DM, Pain O, Hanscombe KB, Jermy B, et al. Multiple
 measures of depression to enhance validity of Major Depressive Disorder in the UK
 Biobank. medRxiv. Cold Spring Harbor Laboratory Press; 2020 Sep
 22;:2020.09.18.20196451.
- 17. Smith DJ, Nicholl BI, Cullen B, Martin D, UI-Haq Z, Evans J, et al. Prevalence and
 Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank:
 Cross-Sectional Study of 172,751 Participants. Potash JB, editor. PLOS ONE. 2013 Nov
 25;8(11):e75362.
- 18. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
 PLINK: rising to the challenge of larger and richer datasets. GigaScience [Internet]. 2015
 Feb 25;4(1):559. Available from: www.cog-genomics.org/plink/1.9/
- 490 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
 491 relationship inference in genome-wide association studies. Bioinformatics. 2010 Nov
 492 15;26(22):2867–73.
- 493 20. Choi SW. choishingwan/GreedyRelated: Function update. 2020 Mar 4.
- 494 21. Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank495 scale genotype datasets. Bioinformatics. 2017 Sep 1;33(17):2776–8.

- 496 22. R Development Core Team. R: A language and environment for statistical computing
 497 [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available from:
 498 http://www.R-project.org
- 23. Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple
 common variants for celiac disease influencing immune gene expression. Nature
 Genetics. Nature Publishing Group; 2010 Apr 1;42(4):295–302.
- Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association
 analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight
 shared genetic risk across populations. Nature Genetics. Nature Publishing Group; 2015
 Sep 1;47(9):979–86.
- The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case
 Control Consortium 2. Genetic risk and a primary role for cell-mediated immune
 mechanisms in multiple sclerosis. Nature. Nature Publishing Group; 2011 Aug
 1;476(7359):214–9.
- Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, et al. A Genome Wide Association Study of Myasthenia Gravis. JAMA neurology. JAMA Neurol; 2015 Apr
 1;72(4):396–404.
- 513 27. Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
 514 meta-analysis characterizes genetic architecture for common psoriasis associated
 515 variants. Nature Communications. Nature Publishing Group; 2017 May 24;8(1):1–8.
- Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, et al. Genetic
 variation at the glycosaminoglycan metabolism pathway contributes to the risk of
 psoriatic arthritis but not psoriasis. Annals of the Rheumatic Diseases. BMJ Publishing
 Group Ltd; 2019 Mar 1;78(3):355–64.
- S20 29. Okada Y, Di Wu, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis
 contributes to biology and drug discovery. Nature. Nature Publishing Group; 2014 Feb
 1;506(7488):376–81.
- 30. Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW, et al.
 Genetic association analyses implicate aberrant regulation of innate and adaptive
 immunity genes in the pathogenesis of systemic lupus erythematosus. Nature Genetics.
 Nature Publishing Group; 2015 Dec 1;47(12):1457–64.
- 527 31. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
 528 PubMed NCBI. GigaScience. 2019 Jul 15;8(7):2091.
- Andres E, Serraj K. Optimal management of pernicious anemia. Journal of blood
 medicine. J Blood Med; 2012;3:97–103.

- Simmonds MJ, Gough SCL. Unravelling the genetic complexity of autoimmune thyroid
 disease: HLA, CTLA-4 and beyond. Clinical and Experimental Immunology. Wiley Blackwell; 2004 Apr 1;136(1):1–10.
- 34. Bradfield JP, Qu H-Q, Wang K, Zhang H, Sleiman PM, Kim CE, et al. A Genome-Wide
 Meta-Analysis of Six Type 1 Diabetes Cohorts Identifies Multiple Associated Loci.
 McCarthy MI, editor. PLoS Genet. Public Library of Science; 2011 Sep
 29;7(9):e1002293.
- Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ. British Medical Journal
 Publishing Group; 2012 Dec 21;345(dec21 3):e8497–7.
- Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
 meta-analysis characterizes genetic architecture for common psoriasis associated
 variants. PubMed NCBI. Nature Communications. 2017 May 24;8:15382.
- International Genetics of Ankylosing Spondylitis Consortium (IGAS). Identification of
 multiple risk variants for ankylosing spondylitis through high-density genotyping of
 immune-related loci. Nature Genetics. Nature Publishing Group; 2013 Jul 1;45(7):730–8.
- 38. Partington RJ, Muller S, Helliwell T, Mallen CD, Sultan AA. Incidence, prevalence and
 treatment burden of polymyalgia rheumatica in the UK over two decades: a populationbased study. Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd; 2018 Dec
 1;77(12):1750–6.
- Humphreys JH, Verstappen SMM, Hyrich KL, Chipping JR, Marshall T, Symmons DPM.
 The incidence of rheumatoid arthritis in the UK: comparisons using the 2010
 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from
 the Norfolk Arthritis Register. Annals of the Rheumatic Diseases. BMJ Publishing Group
 Ltd; 2013 Aug 1;72(8):1315–20.
- for UK Primary Sjögren's Syndrome Registry, Lessard CJ, Li H, Adrianto I, Ice JA,
 Rasmussen A, et al. Variants at multiple loci implicated in both innate and adaptive
 immune responses are associated with Sjögren's syndrome. Nature Genetics. Nat
 Genet; 2013 Oct 6;45(11):1284–92.
- Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and
 prevalence of systemic lupus erythematosus in the UK, 1999–2012. Annals of the
 Rheumatic Diseases. BMJ Publishing Group Ltd; 2016 Jan 1;75(1):136–41.
- Luigi Palla FD. A Fast Method that Uses Polygenic Scores to Estimate the Variance
 Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting a
 Trait. Am J Hum Genet. Elsevier; 2015 Aug 6;97(2):250–9.
- Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working
 Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes

- 567 confounding from polygenicity in genome-wide association studies. Nature Genetics.
 568 2015 Mar;47(3):291–5.
- 569 44. Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al.
 570 Comorbid depression in medical diseases. Nat Rev Dis Primers. Nature Publishing
 571 Group; 2020 Aug 20;6(1):1–22.
- 45. ME L, L T, J B, J C, de Boer P, Mondelli V, et al. Peripheral Blood Cell-Stratified
 Subgroups of Inflamed Depression. Biological Psychiatry. Biol Psychiatry; 2020 Jul
 15;88(2):185–96.
- 575 46. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative
 576 Childhood Stress and Autoimmune Diseases in Adults. Psychosomatic Medicine. 2009
 577 Feb;71(2):243–50.
- 47. Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of
 multiple adverse childhood experiences on health: a systematic review and metaanalysis. The Lancet Public Health. Elsevier; 2017 Aug 1;2(8):e356–66.
- 48. A F, TJ L, C S, N D, L A, T S, et al. Comparison of Sociodemographic and HealthRelated Characteristics of UK Biobank Participants With Those of the General
 Population. American Journal of Epidemiology. Am J Epidemiol; 2017 Nov
 1;186(9):1026–34.
- 49. Batty GD, Gale C, Kivimaki M, Deary I, Bell S. Generalisability of Results from UK
 Biobank: Comparison With a Pooling of 18 Cohort Studies. medRxiv. Cold Spring Harbor
 Laboratory Press; 2019 Aug 13;:19004705.
- 588 50. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of
 589 polygenic risk score usage and performance in diverse human populations. Nature
 590 Communications. Nature Publishing Group; 2019 Jul 25;10(1):1–9.